Bromantane

Bromantane
Clinical data
Trade names	Ladasten
Other names	Bromantan; Bromontan; ADK-709; N-(2-Adamantyl)-4-bromoaniline; N-(2-Adamantyl)-N-(4-Bromophenyl)amine; N-(4-Bromophenyl)-2-adamantanamine
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	US: Unscheduled, not FDA approved; Rx-only (RU);
Pharmacokinetic data
Bioavailability	27.5%
Onset of action	1.5–2 hours (PO)
Elimination half-life	11.21 hours (in humans),; 7 hours (in rats)
Duration of action	8–12 hours (PO)
Identifiers
	IUPAC name N-(4-Bromophenyl)adamantan-2-amine;
CAS Number	87913-26-6 ;
PubChem CID	4660557;
ChemSpider	3849628 ;
UNII	N1ILS53XWK;
CompTox Dashboard (EPA)	DTXSID40405333 ;
ECHA InfoCard	100.213.907
Chemical and physical data
Formula	C16H20BrN
Molar mass	306.247 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C2CC3CC1CC(C2)C3NC4=CC=C(C=C4)Br;
	InChI InChI=1S/C16H20BrN/c17-14-1-3-15(4-2-14)18-16-12-6-10-5-11(8-12)9-13(16)7-10/h1-4,10-13,16,18H,5-9H2 ; Key:LWJALJDRFBXHKX-UHFFFAOYSA-N ;
	(verify)

Bromantane, sold under the brand name Ladasten, is an atypical central nervous system (CNS) stimulant and anxiolytic drug of the adamantane family that is related to amantadine and memantine. Medically, it is approved in Russia for the treatment of neurasthenia. Although the effects of bromantane have been determined to be dependent on the dopaminergic and possibly serotonergic neurotransmitter systems, its exact mechanism of action is unknown, and is distinct in its properties relative to typical stimulants such as amphetamine. Bromantane has sometimes been described as an actoprotector (synthetic adaptogen).